Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431859 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2ACNR2CNR1KEAP1 | |
| SCHEMBL4929476 | 0.86 | CYP1A2 (0.45) | SMN1; SMN2KMT2ACNR2CNR1KEAP1 | |
| SCHEMBL4933471 | 0.85 | ATM (0.43) | SMN1; SMN2CNR2CNR1KEAP1NFE2L2 | |
| SCHEMBL1432003 | 0.82 | CNR2 (0.62) | SMN1; SMN2CNR2CNR1 | |
| SCHEMBL4930729 | 0.81 | CNR2 (0.64) | SMN1; SMN2KMT2ACNR2CNR1MEN1 | |
| SCHEMBL4935540 | 0.81 | NPC1 (0.51) | KMT2AMEN1LMNACA1CA2 | |
| SCHEMBL1431678 | 0.79 | KEAP1 (0.49) | SMN1; SMN2CNR2CNR1KEAP1NFE2L2 | |
| SCHEMBL4934332 | 0.78 | CNR2 (0.47) | SMN1; SMN2KMT2ACNR2CNR1KEAP1 | |
| SCHEMBL1432255 | 0.78 | CYP1A2 (0.43) | SMN1; SMN2KMT2ACNR2CNR1KEAP1 | |
| SCHEMBL4927251 | 0.78 | PPARA (0.41) | SMN1; SMN2CNR2CNR1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | CNR2, CNR1, OPRL1 | SMN1; SMN2 893/4885KMT2A 2331/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.